股票代码：002728 股票简称：特一药业 公告编号：2024-020 特一药业集团股份有限公司 2023 年年度股东大会决议公告 本公司及董事会全体成员保证信息披露内容的真实、准确和完整，没有虚假记载、 误导性陈述或重大遗漏。 一、重要提示 1、本次股东大会以现场表决与网络表决相结合的方式召开； 2、本次股东大会未出现否决议案，未变更前次股东大会决议； 3、本次会议无新议案提交表决。 二、会议召开情况 1、会议召集人：公司董事会 2、会议主持人：公司董事长许丹青 3、会议召开时间： （1）现场会议召开时间：2024 年 3 月 28 日下午 2:30； （2）网络投票时间： 2024 年 3 月 28 日，其中，通过深圳证券交易所交易系统进行网络投票的具体时间 为 2024 年 3 月 28 日 9:15—9:25，9:30—11:30 和 13:00—15:00；通过深圳证券交易所互 联网投票系统进行网络投票的具体时间为 2024 年 3 月 28 日 9:15-15:00 的任意时间。 4、会议地点：广东省台山市台城长兴路 9、11 号特一药业集团股份有限公司二楼 会议室 5、召开方式：现场投票与网络投 ...

深圳市福田区深南大道6008号特区报业大厦42、41、31DE、2403、2405 电话(Tel):+86 755 83515666 传真(Fax):+86 755 83515333/83515090 网址(Website): www.grandall.com.cn 国浩律师（深圳）事务所 关于特一药业集团股份有限公司 2023年年度股东大会的法律意见书 法律意见书 1．根据公司召开的第五届董事会第十九次会议审议通过，公司决定召开2023 年年度股东大会。 GLG/SZ/A2957/FY/2024-162 致：特一药业集团股份有限公司 国浩律师（深圳）事务所（以下称"本所"）接受特一药业集团股份有限公司 （以下称"公司"）的委托，指派本所律师出席公司2023年年度股东大会（以下称 "本次股东大会"），对本次股东大会的合法性进行见证。 本所律师根据《中华人民共和国公司法》（以下称"《公司法》"）、《上市 公司股东大会规则》（以下称"《股东大会规则》"）等法律、法规和规范性法律 文件以及《特一药业集团股份有限公司章程》（以下称"《公司章程》"）的规定， 就公司本次股东大会的召集、召开程序、出席会议人员的资格、召集 ...

特一药业集团股份有限公司 关于公司药品对乙酰氨基酚片通过一致性评价的公告 本公司及董事会全体成员保证信息披露内容的真实、准确和完整，没有虚假记载、 误导性陈述或重大遗漏。 特一药业集团股份有限公司(以下简称"公司")于近日获得国家药品监督管理局核准 签发的"对乙酰氨基酚片"的《药品补充申请批准通知书》，经审查，上述药品通过化学 仿制药质量和疗效一致性评价。本次通过一致性评价的对乙酰氨基酚片共有 2 个规格， 分别为 0.3g、0.5g（其中 0.5g 为新增规格），相关情况如下： 股票代码：002728 股票简称：特一药业 公告编号：2024-019 | 药品 | 剂型 | 注册 | 规格 | 药品批准文 | 药品注册 | 申请内容 | 审批结论 | 上市许可 | 生产企业 | | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | | 名称 | | 分类 | | 号 | 标准编号 | | | 持有人 | | | 对乙 酰氨 | 片剂 | 化学 | 0.3g | 国药准字 | YBH0508 | 仿制药质量 和疗效一致 | 通过仿制药 质量和 ...

特一药业集团股份有限公司（以下简称"公司"）董事会于近日收到公司副总经理 张清民先生的书面辞职报告，张清民先生因年龄原因辞去公司副总经理职务。根据《公 司法》及《深圳证券交易所上市公司自律监管指引第 1 号——主板上市公司规范运作》 的相关规定，张清民先生的辞职报告自送达董事会之日起生效。辞职后，张清民先生将 不在公司担任任何职务。 截至本公告日，张清民先生未持有公司股票；张清民先生持有公司 2021 年股票期权 激励计划已获授但尚未行权的股票期权 98,000 份，将由公司根据《2021 年股票期权激 励计划》的规定予以注销（在办理期权注销手续期间，如遇公司权益分派事项导致期权 数量发生调整，届时将根据实际期权数量予以注销）。 股票代码：002728 股票简称：特一药业 公告编号：2024-018 特一药业集团股份有限公司 关于公司高级管理人员辞职的公告 本公司及董事会全体成员保证信息披露内容的真实、准确和完整，没有虚假记载、 误导性陈述或重大遗漏。 张清民先生辞去副总经理职务不会对公司的生产经营产生重大影响。张清民先生在 担任公司副总经理职务期间恪尽职守、勤勉尽责，公司董事会对张清民先生为公司所做 出的贡 ...

核心产品止咳宝片销量破十亿片，盈利能力稳步提升 [T重ab要le财_P务ro指fit标] 单位:百万元 资料来源： wind，华安证券研究所 | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | |----------------------------------------|---------|-------|-------|-------------------------|-------------------------|---------------|-------------|----------------|--------------------| | [资Ta产 bl负e_债Fi 表 nace] \n会计年度 | \n2023A | 2024E | 2025E | 单位:百万元 \n 2026E | 利润表 \n 会计年度 | 2023A | \n2024E | 单位 \n 2025E | : 百万元 \n 2026E | | 流动资产 | 1105 | 1499 | 1906 | 2447 | 营业收入 | 1067 ...

特一药业集团股份有限公司 关于举行 2023 年度网上业绩说明会的通知 本公司及董事会全体成员保证信息披露内容的真实、准确和完整，没有虚假记载、 误导性陈述或重大遗漏。 特一药业集团股份有限公司（以下简称"公司"）定于 2024 年 3 月 15 日（周五） 15:00-17:00 在全景网举办 2023 年度业绩说明会，本次年度业绩说明会将采用网络远程 的方式举行，投资者可登陆全景网"投资者关系互动平台"（http://ir.p5w.net）参与本次 年度业绩说明会。 股票代码：002728 股票简称：特一药业 公告编号：2024-017 （问题征集专题页面二维码） 特此公告。 特一药业集团股份有限公司董事会 2024 年 3 月 13 日 出席本次说明会的人员有：公司董事长、总经理许丹青先生；副董事长、副总经理 许松青先生；董事、副总经理、财务总监、董事会秘书陈习良先生；董事卢北京先生； 独立董事曹艳铭女士；独立董事李桂生先生；东莞证券保荐代表人郭彬先生。 为充分尊重投资者、提升交流的针对性，现就公司 2023 年度业绩说明会提前向投 资者公开征集问题，广泛听取投资者的意见和建议。投资者可于 2024 年 ...

公司研究 事件：公司发布 2023 年年报，实现营业收入、归母净利润、扣非归母净利润分 别为 10.67/2.53/2.49 亿元，同比+20.38%/42.07%/43.61%。经营性净现金流 1.99 亿元，同比-46.58%；EPS（基本）0.77 元。公司拟向全体股东每 10 股派 发现金红利 5.00 元（含税），以资本公积金向全体股东每 10 股转增 4 股。股 利支付率为 72%。业绩符合市场预期。 点评： 止咳宝片增长强劲，驱动公司盈利能力显著提升。2023 年止咳宝片销量突破 10 亿片，同比增长 91%，比 2019 年增长 41%。经测算，2023 年止咳宝片营收占 比约 43%，同比增加 16pp，显著增厚公司业绩。2023 年销售毛利率同比+7.11pp 至 56.15%，销售净利率同比+3.62pp 至 23.72%。其中，销售/管理/研发/财务 费用率分别同比+3.10/-0.44/-0.25/-1.96pp 至 16.34%/6.21%/4.04%/0.45%。 2023 年公司加大了品牌建设和市场推广力度，销售费用增幅较大，随着特一品 牌知名度的提升，我们预计止咳宝片及其他特 ...

Financial Performance - The company's operating revenue for 2023 reached ¥1,067,212,110.88, representing a 20.38% increase compared to ¥886,570,938.60 in 2022[20]. - The net profit attributable to shareholders was ¥253,175,789.62, marking a 42.07% increase from ¥178,204,104.28 in the previous year[20]. - The net profit after deducting non-recurring gains and losses was ¥249,012,081.13, which is a 43.61% increase from ¥171,371,215.85 in 2022[20]. - Basic and diluted earnings per share were both ¥0.77, up 35.09% from ¥0.57 in 2022[20]. - The weighted average return on net assets increased to 16.57%, compared to 13.98% in the previous year[20]. - The company reported a total revenue of 1,067.21 million yuan in 2023, representing a year-on-year increase of 20.38%[42]. - The net profit attributable to shareholders reached 253.18 million yuan, reflecting a year-on-year growth of 42.07%[42]. - The company achieved a net profit of ¥253,175,789.62 for the fiscal year 2023, with a distributable profit of ¥227,586,694.16 after statutory surplus reserve allocation[159]. Cash Flow and Investments - The net cash flow from operating activities decreased by 46.58% to ¥198,557,705.41 from ¥371,658,160.26 in the previous year[20]. - Operating cash inflow decreased by 2.64% to ¥946,324,466.30, while cash outflow increased by 24.56% to ¥747,766,760.89, resulting in a net cash flow of ¥198,557,705.41, down 46.58%[63]. - Investment cash inflow rose significantly by 81.82% to ¥73,515,945.72, while outflow increased by 10.63% to ¥159,046,533.57, leading to a net cash flow of -¥85,530,587.85[63]. - Financing cash inflow increased by 45.32% to ¥1,109,460,426.76, while outflow rose by 40.51% to ¥1,214,902,277.03, resulting in a net cash flow of -¥105,441,850.27[63]. - Cash and cash equivalents increased by only ¥7,585,267.29, a decline of 95.46% compared to the previous year[64]. Assets and Liabilities - Total assets at the end of 2023 were approximately ¥2.51 billion, a decrease of 1.30% compared to the end of 2022[21]. - Net assets attributable to shareholders of the listed company increased by 43.30% to approximately ¥2.01 billion at the end of 2023[21]. - Total assets included cash of ¥647,247,165.22, accounting for 25.76% of total assets, down from 29.06%[66]. - Inventory increased to ¥271,831,790.86, representing 10.82% of total assets, up from 8.18% due to increased sales[66]. - Fixed assets rose to ¥524,538,600.29, accounting for 20.88% of total assets, up from 14.42% due to projects being completed[66]. - Short-term borrowings decreased to ¥306,000,000.00, down 12.71% from ¥633,680,000.00, primarily due to repayments[66]. Research and Development - The company holds 33 invention patents, 22 design patents, and 8 utility model patents as of the end of the reporting period[39]. - The company is focusing on technological innovation and collaboration with research institutions to improve product quality and efficacy[39]. - The company is advancing multiple R&D projects aimed at improving product quality and expanding market share[62]. - R&D investment increased to ¥53,167,141.27 in 2023, up 22.50% from ¥43,401,780.87 in 2022, representing 4.98% of revenue[63]. - The number of R&D personnel increased by 11.52% to 213, with a notable rise in the number of master's degree holders by 50%[62]. Market and Product Strategy - The company focuses on the research, production, and sales of traditional Chinese medicine, chemical preparations, and chemical raw materials[34]. - The company's core product, Cough Relief Tablets, achieved sales of over 1 billion pieces in 2023, contributing significantly to revenue growth[41]. - The marketing strategy includes a shift from a distributor model to direct sales to retail terminals, aiming to expand sales channels[38]. - The company plans to enhance brand awareness and market promotion, which has already led to increased sales of Cough Relief Tablets and other products[42]. - The company aims to expand the market for its core product, the cough remedy, targeting a sales increase in underrepresented regions[100]. Corporate Governance - The company emphasizes strict adherence to corporate governance standards, ensuring that all shareholders, especially minority shareholders, have equal rights and can fully exercise their rights[121]. - The company maintains independence from its controlling shareholder in terms of assets, personnel, finance, and operations, ensuring a complete and autonomous business system[124]. - The company has established a comprehensive human resources management system, independent of the controlling shareholder, ensuring that all senior management personnel are employed and compensated solely by the company[124]. - The company has implemented effective measures to protect the legal rights of investors and ensure transparent information disclosure, complying with relevant laws and regulations[121][122]. - The company confirms that its governance practices align with the regulations set forth by the China Securities Regulatory Commission, with no significant discrepancies[123]. Environmental Responsibility - The company is committed to environmental protection and has increased investments in upgrading pollution control facilities to comply with stricter regulations[113]. - The company has implemented strict measures to comply with environmental regulations during its operations[180]. - The company has a wastewater treatment capacity of 1,320 tons per day, achieving discharge standards of COD around 20 mg/L, ammonia nitrogen at 0.1 mg/L, total phosphorus at 0.1 mg/L, and total nitrogen at 1.1 mg/L[186]. - The company invested approximately 6.1124 million yuan in environmental governance and protection in 2023, focusing on wastewater and waste gas treatment, solid waste management, and noise control[194]. - The company has achieved a significant reduction in pollutant discharge through continuous technological improvements and increased environmental investment[188]. Employee and Talent Management - The total number of employees at the end of the reporting period was 1,346, with 748 in the parent company and 598 in major subsidiaries[146]. - The company has established a training plan to enhance talent development, ensuring a stable and vibrant workforce[148]. - The company has a structured salary policy based on job value assessment and performance evaluation[147]. - The company has no labor outsourcing applicable during the reporting period[148]. - The company has a total of 8 employees with master's degrees, 228 with bachelor's degrees, and 292 with associate degrees[146]. Shareholder Engagement and Profit Distribution - The company follows a profit distribution policy that mandates at least 15% of the distributable profit to be distributed in cash if the company is profitable[149]. - The proposed cash dividend distribution is ¥5.00 per 10 shares (before tax), totaling ¥182,445,565, which represents 35.26% of the company's distributable profit[160]. - The company has a cumulative distributable profit of ¥517,500,063.81 as of the end of the reporting period[159]. - Independent directors have fulfilled their responsibilities in the decision-making process regarding the cash dividend policy[156]. - The company is implementing a stock option incentive plan, with 400,000 options granted at an exercise price of ¥14.22 per share[163].

特一药业集团股份有限公司 审计报告 大信审字[2024]第 5-00015 号 大信会计师事务所(特殊普通合伙) WUYIGE CERTIFIED PUBLIC ACCOUNTANTS LLP. 您可使用手机"扫一扫"或进入"注册会计师行业统一监管平台（http://acc.mof.gov.cn）"进行查现 mor.gov.cn) 报告编码:京249Y WUYIGE Certified Public Accoun Room 2206 22/F Xuevuan International Top No.1 Zhichun Road Hairlian Dist Beijing,China,100083 审计报告 大信审字[2024]第 5-00015 号 特一药业集团股份有限公司全体股东: 一、审计意见 我们审计了特一药业集团股份有限公司(以下简称"贵公司")的财务报表,包括 2023 年 12 月 31 日的合并及母公司资产负债表, 2023 年度的合并及母公司利润表、合并及母公司 现金流量表、合并及母公司股东权益变动表,以及财务报表附注。 我们认为,后附的财务报表在所有重大方面按照企业会计准则的规定编制,公允 ...

股票代码：002728 股票简称：特一药业 公告编号：2024-016 特一药业集团股份有限公司 关于召开 2023 年年度股东大会的通知 根据《公司法》和《公司章程》的规定，公司于 2024 年 3 月 7 日召开第五届董事 会第十九次会议，现决定于 2024 年 3 月 28 日下午 2:30 在公司会议室召开 2023 年年度 股东大会（以下简称"本次股东大会"），现就召开本次股东大会的相关事项通知如下： 一、召开会议的基本情况 1、股东大会届次：2023 年年度股东大会 2、股东大会召集人：公司董事会 3、会议召开的合法、合规性：本次股东大会的召开符合有关法律、法规和《公司 章程》的规定。 4、 会议时间：2024 年 3 月 28 日下午 2:30 （1）现场会议召开时间：2024 年 3 月 28 日下午 2:30； 7、会议出席对象： （1）在股权登记日持有公司股份的普通股股东或其代理人； 于股权登记日下午收市时在中国结算深圳分公司登记在册的公司全体普通股股东 均有权出席股东大会，并可以以书面形式委托代理人出席会议和参加表决，该股东代理 人不必是本公司股东。 1 （2）公司董事、监事和高级管理人 ...